Genzyme General
This article was originally published in The Gray Sheet
Executive Summary
Collaboration with a research group at The Toronto Hospital will develop cell-based therapies to treat cardiovascular disease. The partners' initial focus is on developing a treatment involving transplantation of cultured autologous cardiomyocytes into the scar tissue that replaces heart muscle after a heart attack. Clinical trials are expected to begin in the second half of 2000. Genzyme gains rights to the technology in exchange for funding all R&D and commercialization efforts
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.